A Comparison of 2019 Industry vs Non-industry-Sponsored Trials

GlobalData analysed the number of clinical trials of both industry and non-industry-sponsored trials with start dates between January 2019 and December 2019.

By GlobalData Healthcare

methamphetamine addiction trial — Credit: Minerva Studio / Shutterstock.

GlobalData analysed the number of clinical trials of both industry and non-industry-sponsored trials with start dates between January 2019 and December 2019.

Free Case Study

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges

by Suvoda

Enter your details here to receive your free Case Study.

By clicking the Download Free Case Study button, you accept the terms and conditions and acknowledge that your data will be used as described in the Suvoda privacy policy By downloading this Case Study, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

GlobalData analysed trials with industry and non-industry sponsors. Figure 1 shows that overall non-industry sponsors conducted more trials than industry sponsors in 2019. Industry sponsors conducted the highest percentage of trials in Q4 at 46.9%, whereas non-industry sponsors had the highest percentage of trials in Q1 at 67.6%.

After further analysis, Novartis had conducted the highest amount of trials in 2019 for an industry sponsor, whereas Cairo University had conducted the most amount of trials for a non-industry sponsor. Industry-sponsored trials were the lowest in Q3 at 32.9% and non-industry-sponsored trials were the lowest in Q4 at 53.1%. Overall the US had conducted the highest amount of trials for 2019, followed by China.

Free Case Study

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

by Suvoda

Enter your details here to receive your free Case Study.

A Comparison of 2019 Industry vs Non-industry-Sponsored Trials

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

GlobalData Healthcare

Schizophrenia accounts for 3.3% share of global Central Nervous System clinical trial activity in 2021

Lupus Erythematosus accounts for 12.2% share of global Immunology clinical trial activity in 2021

Depression accounts for 8.7% share of global Central Nervous System clinical trial activity in 2021

THANK YOU

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

Related Companies

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

Clinical Trials Arena Pipeline Moves

Clinical Trials Arena Weekly Roundup

Pharma Technology Focus Magazine

THANK YOU